Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

Bange E, Marmarelis ME, Hwang WT, Yang YX, Thompson JC, Rosenbaum J, Bauml JM, Ciunci C, Alley EW, Cohen RB, Langer CJ, Carpenter E, Aggarwal C.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00326. Epub 2019 May 10.

2.

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ.

JAMA Oncol. 2019 Jul 11. doi: 10.1001/jamaoncol.2019.1449. [Epub ahead of print]

PMID:
31294762
3.

Integrating principles of military team development into family medicine education.

Dixon MA, Williams-Wonnum SJ, Alley ES, Hyer SM.

Int J Psychiatry Med. 2019 Sep;54(4-5):336-343. doi: 10.1177/0091217419861560. Epub 2019 Jul 8. No abstract available.

PMID:
31282777
4.

Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.

Clin Cancer Res. 2019 Jul 1. doi: 10.1158/1078-0432.CCR-19-0070. [Epub ahead of print]

PMID:
31263030
5.

Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.

Berger I, Cengel KA, Simone CB 2nd, Alley EW, Roshkovan L, Haas AR, Patel AM, Khalid U, Culligan MJ, McNulty S, Singhal S, Friedberg JS, Katz SI.

Lung Cancer. 2019 Jun;132:94-98. doi: 10.1016/j.lungcan.2019.03.026. Epub 2019 Mar 26.

PMID:
31097101
6.

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00107. Epub 2018 Aug 31.

7.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.

JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305.

PMID:
30325992
8.

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.

Mol Ther. 2018 May 2;26(5):1198-1205. doi: 10.1016/j.ymthe.2018.02.015. Epub 2018 Feb 21.

9.

Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.

Aggarwal C, Cohen RB, Yu E, Hwang WT, Bauml JM, Alley E, Evans TL, Langer CJ.

Clin Lung Cancer. 2018 Mar;19(2):157-162. doi: 10.1016/j.cllc.2017.10.007. Epub 2017 Oct 19.

PMID:
29129435
10.

The value of delayed phase enhanced imaging in malignant pleural mesothelioma.

Patel AM, Berger I, Wileyto EP, Khalid U, Torigian DA, Nachiappan AC, Barbosa EM Jr, Gefter WB, Galperin-Aizenberg M, Gupta NK, Simone CB 2nd, Haas AR, Alley EW, Singhal S, Cengel KA, Katz SI.

J Thorac Dis. 2017 Aug;9(8):2344-2349. doi: 10.21037/jtd.2017.07.86.

11.

Associated factors of readiness to change in young adult risky drinkers.

Alley ES, Velasquez MM, von Sternberg K.

Am J Drug Alcohol Abuse. 2018;44(3):348-357. doi: 10.1080/00952990.2017.1363768. Epub 2017 Aug 22.

PMID:
28829630
12.

Immunotherapy and radiation therapy for malignant pleural mesothelioma.

Alley EW, Katz SI, Cengel KA, Simone CB 2nd.

Transl Lung Cancer Res. 2017 Apr;6(2):212-219. doi: 10.21037/tlcr.2017.04.01. Review.

13.

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E.

Lancet Oncol. 2017 May;18(5):623-630. doi: 10.1016/S1470-2045(17)30169-9. Epub 2017 Mar 11.

PMID:
28291584
14.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

PMID:
28285682
15.

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.

Bagley SJ, Vitale S, Zhang S, Aggarwal C, Evans TL, Alley EW, Cohen RB, Langer CJ, Blair IA, Vachani A, Whitehead AS.

Clin Lung Cancer. 2017 Mar;18(2):e143-e149. doi: 10.1016/j.cllc.2016.10.010. Epub 2016 Oct 26.

16.

Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.

Friedberg JS, Simone CB 2nd, Culligan MJ, Barsky AR, Doucette A, McNulty S, Hahn SM, Alley E, Sterman DH, Glatstein E, Cengel KA.

Ann Thorac Surg. 2017 Mar;103(3):912-919. doi: 10.1016/j.athoracsur.2016.08.071. Epub 2016 Nov 5.

17.

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors.

Fox AJ, Hiemenz MC, Lieberman DB, Sukhadia S, Li B, Grubb J, Candrea P, Ganapathy K, Zhao J, Roth D, Alley E, Loren A, Morrissette JJ.

J Vis Exp. 2016 Sep 20;(115). doi: 10.3791/52758. Review.

18.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

19.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM.

Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11.

20.

Interactive Multimedia Tailored to Improve Diabetes Self-Management.

Wood FG, Alley E, Baer S, Johnson R.

Nurs Clin North Am. 2015 Sep;50(3):565-76. doi: 10.1016/j.cnur.2015.05.009. Review.

PMID:
26333610
21.

Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.

Azzato EM, Deshpande C, Aikawa V, Aggarwal C, Alley E, Jacobs B, Morrissette J, Daber R.

Anticancer Res. 2015 May;35(5):3007-12.

PMID:
25964588
22.

Neuraxial anesthesia for outpatients.

Alley EA, Mulory MF.

Anesthesiol Clin. 2014 Jun;32(2):357-69. doi: 10.1016/j.anclin.2014.02.007. Review.

PMID:
24882123
23.

Predictors of readiness to change young adult drug use in community health settings.

Alley ES, Ryan T, von Sternberg K.

Subst Use Misuse. 2014 Feb;49(3):253-61. doi: 10.3109/10826084.2013.825920. Epub 2013 Aug 23.

PMID:
23971893
24.

Thymic neuroendocrine tumor presenting with the ectopic ACTH syndrome.

Barbieri JS, Seshasai R, Shemesh A, Sedrak M, Hoffman B, Alley EW.

J Thorac Oncol. 2013 Jun;8(6):e57-8. doi: 10.1097/JTO.0b013e31828c2900. No abstract available.

25.

Management of bladder volumes when using neuraxial anesthesia.

Mulroy MF, Alley EA.

Int Anesthesiol Clin. 2012 Winter;50(1):101-10. doi: 10.1097/AIA.0b013e318217754d. Review.

PMID:
22227426
26.

Determination of methanol in biodiesel by headspace solid phase microextraction.

Paraschivescu MC, Alley EG, French WT, Hernandez R, Armbrust K.

Bioresour Technol. 2008 Sep;99(13):5901-5. Epub 2007 Nov 26.

PMID:
18037289
27.

Development of a heterogeneous catalytic cracking reactor utilizing online mass spectrometry analysis.

Benson TJ, Holmes WE, White MG, French WT, Alley EG, Hernandez R.

J Chromatogr A. 2007 Nov 23;1172(2):204-8. Epub 2007 Oct 2.

PMID:
17959186
28.

Amine promoted, metal enhanced degradation of Mirex under high temperature conditions.

Jallad KN, Lynn BC, Alley EG.

J Hazard Mater. 2006 Jul 31;135(1-3):437-42. Epub 2006 Jan 4.

PMID:
16387436
29.

Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study.

Little MP, Breitling LP, Basáñez MG, Alley ES, Boatin BA.

Lancet. 2004 May 8;363(9420):1514-21.

PMID:
15135599
30.

Incidence of blindness during the Onchocerciasis control programme in western Africa, 1971-2002.

Little MP, Basanez MG, Breitling LP, Boatin BA, Alley ES.

J Infect Dis. 2004 May 15;189(10):1932-41. Epub 2004 Apr 27.

PMID:
15122532
31.

Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa.

Borsboom GJ, Boatin BA, Nagelkerke NJ, Agoua H, Akpoboua KL, Alley EW, Bissan Y, Renz A, Yameogo L, Remme JH, Habbema JD.

Filaria J. 2003 Mar 24;2(1):8.

32.

Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods.

Boatin BA, Toé L, Alley ES, Nagelkerke NJ, Borsboom G, Habbema JD.

Parasitology. 2002 Dec;125(Pt 6):545-52.

PMID:
12553573
33.

Validation of parasite transmission models: the example of onchocerciasis.

Nagelkerke NJ, de Vlas SJ, Alley ES.

Neth J Med. 2002 Aug;60(7 Suppl):44-9; discussion 50-1.

PMID:
12430590
34.

Transient neurologic syndrome in a patient receiving hypobaric lidocaine in the prone jack-knife position.

Alley EA, Pollock JE.

Anesth Analg. 2002 Sep;95(3):757-9, table of contents.

PMID:
12198066
35.

Can ivermectin mass treatments eliminate onchocerciasis in Africa?

Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, Habbema JD.

Bull World Health Organ. 2002;80(5):384-91.

36.

Cutaneous toxicities of cancer therapy.

Alley E, Green R, Schuchter L.

Curr Opin Oncol. 2002 Mar;14(2):212-6. Review.

PMID:
11880713
37.

Hyperbaric spinal levobupivacaine: a comparison to racemic bupivacaine in volunteers.

Alley EA, Kopacz DJ, McDonald SB, Liu SS.

Anesth Analg. 2002 Jan;94(1):188-93, table of contents.

PMID:
11772826
38.

Eliminating onchocerciasis after 14 years of vector control: a proved strategy.

Hougard JM, Alley ES, Yaméogo L, Dadzie KY, Boatin BA.

J Infect Dis. 2001 Aug 15;184(4):497-503. Epub 2001 Jul 16.

PMID:
11471108
39.

Topical application of diethylcarbamazine to detect onchocerciasis recrudescence in west Africa.

Toè L, Adjami AG, Boatin BA, Back C, Alley ES, Dembélé N, Brika PG, Pearlman E, Unnasch TR.

Trans R Soc Trop Med Hyg. 2000 Sep-Oct;94(5):519-25.

PMID:
11132381
40.

The impact of Mectizan on the transmission of onchocerciasis.

Boatin BA, Hougard JM, Alley ES, Akpoboua LK, Yaméogo L, Dembélé N, Sékétéli A, Dadzie KY.

Ann Trop Med Parasitol. 1998 Apr;92 Suppl 1:S46-60. Review.

PMID:
9861267
41.

Diagnostics in onchocerciasis: future challenges.

Boatin BA, Toé L, Alley ES, Dembélé N, Weiss N, Dadzie KY.

Ann Trop Med Parasitol. 1998 Apr;92 Suppl 1:S41-5. Review.

PMID:
9861266
42.

Patterns of epidemiology and control of onchocerciasis in west Africa.

Boatin B, Molyneux DH, Hougard JM, Christensen OW, Alley ES, Yameogo L, Seketeli A, Dadzie KY.

J Helminthol. 1997 Jun;71(2):91-101. No abstract available.

PMID:
9192715
43.

Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control Programme in west Africa.

Plaisier AP, Alley ES, van Oortmarssen GJ, Boatin BA, Habbema JD.

Bull World Health Organ. 1997;75(3):237-45.

44.

Transcriptional basis for hyporesponsiveness of the human inducible nitric oxide synthase gene to lipopolysaccharide/interferon-gamma.

Zhang X, Laubach VE, Alley EW, Edwards KA, Sherman PA, Russell SW, Murphy WJ.

J Leukoc Biol. 1996 Apr;59(4):575-85.

PMID:
8613707
45.

Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages.

Miller L, Alley EW, Murphy WJ, Russell SW, Hunt JS.

J Leukoc Biol. 1996 Mar;59(3):442-50.

PMID:
8604025
46.

Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa.

Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, De Vlas SJ, Bonneux L, Habbema JD.

J Infect Dis. 1995 Jul;172(1):204-10.

PMID:
7797912
49.
50.

Impact of combined large-scale ivermectin distribution and vector control on transmission of Onchocerca volvulus in the Niger basin, Guinea.

Guillet P, Sékétéli A, Alley ES, Agoua H, Boatin BA, Bissan Y, Akpoboua LK, Quillévéré D, Samba EM.

Bull World Health Organ. 1995;73(2):199-205.

Supplemental Content

Support Center